Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and another hormone, could offer a significant step forward for body treatment. Initial clinical investigations have demonstrated substantial decreases in body fat , conceivably exceeding other obesity therapies . Despite this, more evaluation is needed to completely understand